Boston Scientific posts Q3 net income of $755 million
Reuters
Nov 03
Boston Scientific posts Q3 net income of $755 million
Boston Scientific Corporation reported net sales of $5.1 billion for the third quarter of 2025, an increase of 20.3% compared to $4.2 billion in the same period of 2024. The growth included a 15.3% rise in organic net sales and a 4.2 percentage point positive impact from acquisitions. For the nine months ended September 30, 2025, income before income taxes was $2.7 billion, with net income attributable to common stockholders at $2.2 billion, or $1.49 per share. The period included non-GAAP adjustments such as $669 million in amortization expense and $46 million in goodwill and intangible asset impairment charges. The company continued to focus on developing and marketing medical devices for a broad range of interventional specialties and highlighted the positive effects of recent acquisitions and foreign currency fluctuations on its financial results.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000885725-25-000050), on November 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.